Access to comprehensive genomic insights remains a barrier to truly personalized cancer care. The challenge was to communicate the need for more accessible and actionable diagnostic testing that can guide treatment decisions. The solution presents Illumina’s TruSight Oncology Comprehensive as an in vitro diagnostic test designed to bring advanced genomic profiling closer to patients and communities, helping make personalized oncology care the standard rather than the exception.